Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Melatonin is an indole hormone produced mainly by the pineal gland. We have previously demonstrated that melatonin interferes with estrogen (E(2)) signaling in MCF7 cells by impairing estrogen receptor (ER) pathways. Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E(2)-induced ERalpha-mediated transcription in both estrogen response element- and AP1-containing promoters, whereas ERbeta-mediated transactivation is not inhibited or even activated at certain promoters. We show that the sensitivity of MCF-7 cells to melatonin depends on the ERalpha/ERbeta ratio, and ectopic expression of ERbeta results in MCF-7 cells becoming insensitive to this hormone. Melatonin acts as a calmodulin antagonist inducing conformational changes in the ERalpha-calmodulin (CaM) complex, thus impairing the binding of E(2).ERalpha.CaM complex to DNA and, therefore, preventing ERalpha-dependent transcription. Moreover the mutant ERalpha (K302G,K303G), unable to bind calmodulin, becomes insensitive to melatonin. The effect of melatonin is specific since other related indoles neither interact with CaM nor inhibit ERalpha-mediated transactivation. Interestingly, melatonin does not affect the binding of coactivators to ERalpha, indicating that melatonin action is different from that of current therapeutic anti-estrogens used in breast cancer therapy. Thus, they target ERalpha at different levels, representing two independent ways to control ERalpha activity. It is, therefore, conceivably a synergistic pharmacological effect of melatonin and current anti-estrogen drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Rotating night shifts and risk of breast cancer in women participating in the nurses׳ health study
Schernhammer, E. S., Laden, F., Speizer, F. E., Willett, W. C., Hunter, D. J., Kawachi, I., & Colditz, G. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.20.1563 · Cited by 1,142
Cited by
Zimmermann, P., & Curtis, N. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Melatonin signaling and cell protection function
Luchetti, F., Canonico, B., Betti, M., Arcangeletti, M., Pilolli, F., Piroddi, M., Canesi, L., Papa, S., & Galli, F. (2010) · The FASEB Journal · doi:10.1096/fj.10-154450 · Cited by 341
Night Shift Work and the Risk of Endometrial Cancer
Viswanathan, A. N., Hankinson, S. E., & Schernhammer, E. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2485 · Cited by 338
Melatonin: an inhibitor of breast cancer
Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., et al. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0030 · Cited by 317
Cancer metastasis: Mechanisms of inhibition by melatonin
Su, S., Hsieh, M., Yang, W., Chung, W., Reiter, R. J., & Yang, S. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12370 · Cited by 280
Melatonin–estrogen interactions in breast cancer
Sánchez‐Barceló, E. J., Cos, S., Mediavilla, D., Martínez‐Campa, C., González, A., & Alonso‐González, C. (2005) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00207.x · Cited by 228
“The sensitivity of the MCF-7 human breast cancer cells to melatonin depends on the ERa/ERb ratio and is abolished by ERb overexpression [ 61 ].”
BackgroundSelf-citationMechanisms of cancer inhibition by melatonin
Reiter, R. J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00165.x · Cited by 223
Blask, D. E., Hill, S. M., Dauchy, R. T., Xiang, S., Yuan, L., Duplessis, T., Mao, L., Dauchy, E., & Sauer, L. A. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00888.x · Cited by 187
Circulating melatonin and the risk of breast and endometrial cancer in women
Viswanathan, A. N., & Schernhammer, E. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.002 · Cited by 153
Laborda-Illanes, A., Sánchez-Alcoholado, L., Boutriq, S., Plaza-Andrades, I., Peralta-Linero, J., Alba, E., González-González, A., & Queipo-Ortuño, M. I. (2021) · Cancers · doi:10.3390/cancers13133141 · Cited by 28
Metadata
- Authors
- del Río, B., Pedrero, J. M. G., Martínez-Campa, C., Zuazua, P., Lazo, P. S., & Ramos, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 279
- Issue
- 37
- Pages
- 38294-38302
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2130672089
- Cited by
- 139
- References
- 3
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.